IPSEF Stock Price, Chart, Stats & News
Ipsen S.A. (IPSEF) is a dividend-paying stock with a current dividend yield of 3.29% as of Aug 13, 2026. It pays $3.72 per share over the trailing twelve months and distributes bi-annually. Its dividend has grown at a 8.76% 5-year compound annual rate.
Dividend safety
Dividend coverage looks healthy — IPSEF pays out about 26% of earnings.
IPSEF chart
About
Ipsen S. A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors.
Related lists
Similar securities
Based on sector and market capitalization
